Three new drugs have been approved by the FDA for patients with acute leukemia types and show promising remission rates.
“New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to...
The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies: Impact on the VHA
The Hematopathology Molecular Genetics subcommittee presents recommendations for molecular diagnostic testing in acute myeloid leukemia,...
Researchers assess how patients’ immune systems respond to a flu vaccine after chemotherapy to determine the likelihood of positive immunotherapy...
Characterization of Hematology Consults for Complete Blood Count Abnormalities: A Single Center Experience in the Era of Electronic Consultation
Abstract 2: 2017 AVAHO Meeting
Starting patients on a reduced dose and increasing it gradually while monitoring carefully for adverse events, meant patients did not have to stop...
MADRID – Adding the proteasome inhibitor carfilzomib to induction regimens delivered quicker and deeper remissions.
LUGANO, SWITZERLAND – The immune checkpoint inhibitor avelumab showed efficacy against classical Hodgkin lymphoma among patients with disease...
A combination of 3 different types of inhibitors has recently been shown to be effective in the treatment of patients with multiple myeloma...